G-CSF and immunosuppressive treatments in CPN patients
| . | All patients, n = 108 . |
|---|---|
| Treatment (%) | 54 (47.4%) |
| Treatment indication | |
| Nonsevere bacterial infection | 18/54 (33.3%) |
| Severe bacterial infection | 15/54 (27.8%) |
| Aphtous stomatitis | 13/54 (24.1%) |
| Neutropenia | 7/54 (13%) |
| Asthenia | 1/54 (1.9%) |
| Planned G-CSF treatment | 24/50 (48%) |
| Median duration (days), [IQR] | 1415 [1032-2762] |
| Complete response to G-CSF (%) | 23/24 (96) |
| Sporadic G-CSF treatment | 26/50 (52%) |
| Mediation duration (days), [IQR] | 111 [22-464] |
| Other treatments | 19/54 |
| Response to immunosuppressive treatments | 8/19 (44.4%) |
| Number of immunosuppressive treatments | |
| 1 | 9/19 (47.4%) |
| 2 | 6/19 (31.6%) |
| ≥3 | 4/19 (20%) |
| . | All patients, n = 108 . |
|---|---|
| Treatment (%) | 54 (47.4%) |
| Treatment indication | |
| Nonsevere bacterial infection | 18/54 (33.3%) |
| Severe bacterial infection | 15/54 (27.8%) |
| Aphtous stomatitis | 13/54 (24.1%) |
| Neutropenia | 7/54 (13%) |
| Asthenia | 1/54 (1.9%) |
| Planned G-CSF treatment | 24/50 (48%) |
| Median duration (days), [IQR] | 1415 [1032-2762] |
| Complete response to G-CSF (%) | 23/24 (96) |
| Sporadic G-CSF treatment | 26/50 (52%) |
| Mediation duration (days), [IQR] | 111 [22-464] |
| Other treatments | 19/54 |
| Response to immunosuppressive treatments | 8/19 (44.4%) |
| Number of immunosuppressive treatments | |
| 1 | 9/19 (47.4%) |
| 2 | 6/19 (31.6%) |
| ≥3 | 4/19 (20%) |